InnoSIGN offers its OncoSIGNal technology to gain insight into the functional activity of cellular signaling pathways. mRNA levels transcribed from direct target genes regulated by the pathway transcription factors are translated into pathway activity scores for the ER, AR, PI3K, MAPK, Hedgehog, TGFß, Notch, Wnt, NF-kB and JAK-STAT1/2 pathways, resulting in a quantitative characterization of the cell molecular phenotype.

OncoSIGNal is available for clinical use in breast cancer as a lab-developed test through InnoSIGN’s CLIA laboratory in Mason (OH), for research use through labs in the EU and US as a comprehensive testing service, or as a distributed PCR test for use in a customer laboratory.

The analysis can also be run from RNA-seq data for various cancer and cell types. InnoSIGN utilizes its extensive database with more than 100,000 pathway activity profiles to support drug and diagnostics development.

OncoSIGNal Products & Services for Research-Use-Only

OncoSIGNal Test (G7)

• ER, AR, PI3K, MAPK, Hedgehog, Notch, TGFß pathways
  
• Compatible with FFPE samples from human origin
  
• RT-qPCR testing plates including quality checks on sample input and correct plate filling
  
• Result overview in dedicated OncoSIGNal Report
  
• Allows for in-house testing using standard laboratory equipment
  
• Developed under ISO13485

OncoSIGNal Service Testing

• ER, AR, PI3K, MAPK, Hedgehog, Notch, TGFß and/or Wnt, NF-kB and JAK-STAT1/2 pathways
  
• Compatible with FFPE tissue samples and RNA extracted from cell lines and tissue of human origin
  
• Extensive quality checks on samples, laboratory process and results
  
• Result overview in dedicated OncoSIGNal Report
  
• ISO13485 certified

OncoSIGNal Data Service

• ER, AR, PI3K, MAPK, Hedgehog, Notch, TGFß and/or Wnt, NF-kB and JAK-STAT1/2 pathways
  
• Analysis of full transcriptome RNA sequencing data
  
• Compatible with FASTQ data files
  
• Extensive quality checks on samples and results
  
• Result overview in dedicated OncoSIGNal Report

OncoSIGNal Laboratory Developed Test for clinical use

• Available in the US as LDT for breast cancer via InnoSIGN’s CLIA laboratory (Mason, Ohio)
  
• ER, AR, PI3K, MAPK, Hedgehog, Notch and TGFß pathways
  
• Sample type: FFPE tissue
  
• Indication of tumor-driving pathways
  
• Guiding therapy decisions

  Media

  ---

  OncoSIGNal Products & Services

  pdf

  OncoSIGNal G7 Test

  pdf

  Selection Personalized Therapy Using Computational Models

  pdf

  Enabling precision medicine by unravelling disease pathophysiology

  pdf

  Measurement of activity of developmental signal transduction pathways to quantify stem cell

  pdf